A Study of Tirzepatide Administered by Two Different Devices in Healthy Participants

NCT04004988 · Completed

Last updated 2026-05-28

This clinical trial is testing how two different devices deliver the medication tirzepatide in healthy participants to measure its absorption in the body.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) basic-science study

Participants 47 people

Who can join Ages 21–70 · all sexes Healthy volunteers accepted.

Timeline Started 2019-08 · est. completion 2019-12

Where 1 site · Singapore

What this study is testing ClinicalTrials.gov NCT04004988 ↗

Description as written by the study sponsor.

The purpose of this study is to compare the amount of tirzepatide that gets into the blood stream and how long it takes the body to get rid of it, when given as a solution formulation via an autoinjector versus a conventional prefilled syringe. The tolerability of tirzepatide will also be evaluated and information about any adverse effects experienced will be collected. Screening is required within 28 days prior to the start of the study. For each participant, the total duration of the clinical trial will be about 14 weeks, including screening.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
Prefilled syringe (PFS) Device

PFS used to administer tirzepatide
Auto-injector (AI) Device

AI used to administer tirzepatide

Main thing measured	Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Infinity (AUC0toinf)
Sponsor	Eli Lilly and Company
Conditions studied	Healthy
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04004988 ↗